Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcoritamab + rituximab
- Development stage
- Unknown
- Lead developer
- Genmab
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Epcoritamab + rituximab is an investigational combination therapy being evaluated for the first-line treatment of patients with previously untreated, high-tumor-burden follicular lymphoma. Epcoritamab (Epkinly) is a bispecific IgG1 antibody that simultaneously binds to CD3 on T cells and CD20 on B cells, facilitating T-cell-mediated lysis of malignant B cells. Rituximab is a chimeric monoclonal antibody that targets CD20, inducing cell death through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This specific regimen is the subject of a Phase 2 clinical trial (NCT05783609) led by Dr. Reid Merryman at the Dana-Farber Cancer Institute, representing an effort to move bispecific antibody therapy into earlier lines of treatment for follicular lymphoma.
- Brand names
- EpkinlyRituxanMabThera
- Other names
- epcoritamab-bysp
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on epcoritamab + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcoritamab + rituximab.